Advertisement

International Journal of Hematology

, Volume 110, Issue 3, pp 322–330 | Cite as

VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era

  • Shumpei MizutaEmail author
  • Takahito Kawata
  • Hiroshi Kawabata
  • Noriko Yamane
  • Saya Mononobe
  • Takao Komai
  • Yusuke Koba
  • Naoya Ukyo
  • Akira Tamekane
  • Mitsumasa Watanabe
Original Article

Abstract

The development of effective therapies has enabled long-term survival for many patients with multiple myeloma (MM). However, the administration of antibody drugs, such as daratumumab, which bind to plasma cell (PC) surface proteins, may prevent PC detection by flow cytometry. We propose VS38 as an alternative antibody for CD38. VS38 recognizes cytoskeleton-linking membrane protein 63 (CLIMP-63) on the rough endoplasmic reticulum, and this protein may be expressed in secretory cells. We investigated VS38 staining in normal hematopoietic cells from five control samples, as well as PCs from 21 patients with plasma cell disorder (PCD). In normal hematopoietic cells, although VS38-stained monocytes, myeloid cells, and a subpopulation of B cells, PCs were significantly and brightly stained by VS38. There was no significant difference in VS38 staining between normal and abnormal PCs obtained from five patients with monoclonal gammopathy of undetermined significance. Furthermore, PCs in 21 PCD cases were clearly identified by VS38 in all cases, in contrast to CD38, even in daratumumab-administered patients whose CD38 epitopes on PCs were masked. These results suggest that the use of the VS38 antibody in flow cytometry contributes to PC detection, independent of therapeutic treatment.

Keywords

Multiple myeloma VS38 Daratumumab CD38 Flow cytometry 

Notes

Acknowledgements

We are grateful to Mr. Shinichiro Matsuki (AGMC) for his generous support of our work. We would like to thank Editage (www.editage.jp) for English language editing.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12185_2019_2685_MOESM1_ESM.docx (2 mb)
Supplementary file1 (DOCX 2008 kb)

References

  1. 1.
    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–23.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–68.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017;28:2503–10.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64.CrossRefPubMedGoogle Scholar
  8. 8.
    van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102:e368–e370370.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol. 1994;47:418–22.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shanks JH, Banerjee SS. VS38 immunostaining in melanocytic lesions. J Clin Pathol. 1996;49:205–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sulzbacher I, Fuchs M, Chott A, Lang S. Expression of VS38 in osteoblasts and stroma cells of bone tumors. Pathol Res Pract. 1997;193:613–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Banerjee SS, Shanks JH, Hasleton PS. VS38 immunostaining in neuroendocrine tumours. Histopathology. 1997;30:256–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Banham AH, Turley H, Pulford K, Gatter K, Mason DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J Clin Pathol. 1997;50:485–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hookway ES, Orosz Z, Uchihara Y, Grigoriadis A, Hassan AB, Oppermann U, et al. Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions. Clin Sarcoma Res. 2017;7:17.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hasilik A, Pohlmann R, Olsen RL, von Figura K. Myeloperoxidase is synthesized as larger phosphorylated precursor. EMBO J. 1984;3:2671–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, et al. EuroFlow group. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom. 2016; 90:91-100.CrossRefPubMedGoogle Scholar
  20. 20.
    Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88:168–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Sondergeld P, van de Donk NW, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13:599–609.PubMedGoogle Scholar
  22. 22.
    Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959–70.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Shumpei Mizuta
    • 1
    • 2
    Email author
  • Takahito Kawata
    • 3
    • 4
  • Hiroshi Kawabata
    • 1
  • Noriko Yamane
    • 1
  • Saya Mononobe
    • 1
  • Takao Komai
    • 1
  • Yusuke Koba
    • 3
  • Naoya Ukyo
    • 3
  • Akira Tamekane
    • 3
  • Mitsumasa Watanabe
    • 3
  1. 1.Department of Clinical LaboratoryHyogo Prefectural Amagasaki General Medical CenterHyogoJapan
  2. 2.Laboratory of Hematology, Division of Medical BiophysicsKobe University Graduate School of Health SciencesHyogoJapan
  3. 3.Department of HematologyHyogo Prefectural Amagasaki General Medical CenterHyogoJapan
  4. 4.Department of Hematology and Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations